Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some core renal-toxicity monitoring and renal impairment risk statements are supported by the provided label excerpts (5.8, 8.6). However, many mechanistic and kidney-specific causal claims (oxidative stress, inflammation/fibrosis, direct renal cell damage) are not supported by the supplied sections, and multiple statements rely on label context that is not included (boxed warnings, contraindications, drug interactions, specific geriatric phrasing).
Category Scores
Accurate Statements
Methotrexate is primarily excreted by the kidneys.
12.3 Pharmacokinetics - Excretion (methotrexate primarily undergoes renal excretion by glomerular filtration and active tubular secretion).
Regular monitoring of kidney function is essential to detect early signs of kidney damage during methotrexate therapy.
5.8 Renal Toxicity (Monitor renal function at baseline, periodically during treatment and as clinically indicated).
Dose adjustment or discontinuation of methotrexate may be necessary to prevent kidney damage.
5.8 Renal Toxicity (Withhold or discontinue for severe renal toxicity); 8.6 Renal Impairment (Reduce the dosage or discontinue as appropriate).
Pre-existing kidney disease increases the risk of methotrexate-induced kidney damage.
8.6 Renal Impairment (Patients with renal impairment are at increased risk for methotrexate adverse reactions; Closely monitor; Reduce dosage or discontinue).
Unsupported Statements
Methotrexate can directly damage renal cells, leading to inflammation and fibrosis.
Provided excerpts only state that TREXALL can cause renal toxicity (including irreversible acute renal failure) and give monitoring/withholding guidance; they do not describe direct renal cell damage, inflammation, or fibrosis.
Methotrexate can induce oxidative stress.
No oxidative stress mechanism is mentioned in the provided label excerpts.
Methotrexate-induced oxidative stress can damage renal cells and contribute to kidney dysfunction.
Oxidative stress and its renal downstream effects are not mentioned in the provided label excerpts.
Methotrexate can trigger an inflammatory response in the kidneys.
Renal toxicity is mentioned, but an inflammatory response in kidneys is not described in the provided excerpts.
Methotrexate-triggered kidney inflammation can lead to tissue damage and fibrosis.
No kidney inflammation-to-fibrosis causal pathway is described in the provided excerpts.
Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), can increase the risk of kidney damage when used concomitantly with methotrexate.
No drug-drug interaction information is included in the provided label excerpts.
Longer treatment durations of methotrexate increase the risk of kidney damage.
The provided excerpts do not state a relationship between duration of therapy and risk of renal damage.
Alternative treatments, such as biologics or disease-modifying antirheumatic drugs (DMARDs), may be considered for patients with pre-existing kidney disease or those at high risk of kidney damage.
The provided excerpts mention availability of alternative therapy in the context of withhold/discontinue decisions, but do not specify biologics/DMARDs or link them to pre-existing kidney disease in the provided text.
Methotrexate has a narrow therapeutic index.
Not mentioned in the provided label excerpts.
Contradictions
Important Omissions
Drug interactions (e.g., NSAIDs) cautions/required warnings are not present in the supplied label excerpts; therefore interaction-related claims cannot be verified against the label content provided.
Importance:
Moderate
Boxed warnings and contraindications text were not provided; these may contain material safety statements and are necessary to fully assess label alignment for safety-related claims.
Importance:
Moderate
Geriatric section beyond the statement about insufficient numbers of subjects (8.5) and additional renal-related labeling context are not provided; therefore claims attributing susceptibility specifically to natural age-related kidney decline are not verifiable.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
Several mechanistic/cause-and-effect claims about renal injury (oxidative stress, inflammation, fibrosis, direct renal cell damage) are not supported by the provided label excerpts, and an NSAID interaction claim is not supported because drug interaction labeling content was not included. Monitoring and renal impairment risk guidance aligns with the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims add specific mechanistic or drug-interaction details (oxidative stress, inflammatory/fibrotic kidney injury, NSAID concomitant risk) that are not supported by the provided label excerpts; additionally, boxed warnings/contraindications/drug-interactions sections were not supplied, limiting verification.
Suggested Improvement
Restrict claims to the provided label-supported renal toxicity content (renal toxicity, monitoring schedule, withholding/discontinuation, and renal impairment increased risk) and avoid unsupported mechanistic or interaction-specific assertions unless the corresponding label sections are provided and confirm the wording.